Living With Narcolepsy?
The aim of this study is to quantify the change in blood pressure when participants with narcolepsy treated with high-sodium oxybate are transitioned to XYWAV, a low-sodium oxybate. The results of this study may provide health care providers (HCPs), patients, and payers with important new information regarding BP changes related to differences in sodium content between available oxybates for the treatment of narcolepsy.
To qualify, you must:
- Be 18 to 70 years of age.
- Have a documented diagnosis of Type 1 or Type 2 narcolepsy.
- Have been receiving a dose of high-sodium oxybate (eg, XYREM) of 6 to 9 g/night (inclusive) for a minimum of 6 consecutive weeks prior to screening.
- If female, must not be pregnant or breastfeeding.
*Other criteria also apply
Contribute to the advancement of medical knowledge and treatments, while receiving expert medical care under close supervision.
The M3 Wake Research Network has powered innovation with over 9,100 Successful Clinical Trials in patients from 6 months to 85 years.
Patient safety is paramount with strict protocols and ethical guidelines, minimizing risks and ensuring thorough monitoring throughout the trial.